JP2017536341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536341A5 JP2017536341A5 JP2017518516A JP2017518516A JP2017536341A5 JP 2017536341 A5 JP2017536341 A5 JP 2017536341A5 JP 2017518516 A JP2017518516 A JP 2017518516A JP 2017518516 A JP2017518516 A JP 2017518516A JP 2017536341 A5 JP2017536341 A5 JP 2017536341A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ror1
- domain
- fab
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188378.5 | 2014-10-09 | ||
| EP14188378 | 2014-10-09 | ||
| EP14188727 | 2014-10-14 | ||
| EP14188728.1 | 2014-10-14 | ||
| EP14188728 | 2014-10-14 | ||
| EP14188727.3 | 2014-10-14 | ||
| PCT/EP2015/073309 WO2016055593A1 (en) | 2014-10-09 | 2015-10-08 | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536341A JP2017536341A (ja) | 2017-12-07 |
| JP2017536341A5 true JP2017536341A5 (Direct) | 2018-11-22 |
Family
ID=54291293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518516A Pending JP2017536341A (ja) | 2014-10-09 | 2015-10-08 | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170306044A1 (Direct) |
| EP (1) | EP3204416A1 (Direct) |
| JP (1) | JP2017536341A (Direct) |
| AU (1) | AU2015329966A1 (Direct) |
| CA (1) | CA2963696A1 (Direct) |
| WO (1) | WO2016055593A1 (Direct) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107903325B (zh) | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| JP6444874B2 (ja) | 2012-10-08 | 2018-12-26 | ロシュ グリクアート アーゲー | ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法 |
| NZ708182A (en) | 2013-02-26 | 2019-08-30 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| SMT202400235T1 (it) | 2014-08-04 | 2024-07-09 | Hoffmann La Roche | Molecole bispecifiche leganti l’antigene di attivazione delle cellule t |
| HRP20201747T1 (hr) | 2014-11-20 | 2020-12-25 | F. Hoffmann - La Roche Ag | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 |
| CN107206072B (zh) | 2014-11-20 | 2022-01-21 | 豪夫迈·罗氏有限公司 | T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD-1轴结合拮抗剂的组合疗法 |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| BR112018000835A2 (pt) | 2015-10-02 | 2018-09-11 | Hoffmann La Roche | molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo |
| EA201891066A1 (ru) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | Антитела к ror1 |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| EP3400246B1 (en) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| UA125718C2 (uk) | 2016-01-20 | 2022-05-25 | Зе Скріппс Ресеарч Інстітьют | Композиції антитіл до ror1 і пов'язані з ними способи |
| AU2017233121B2 (en) | 2016-03-15 | 2023-12-21 | Itabmed (Hk) Limited | Multispecific Fab fusion proteins and use thereof |
| ES2947230T3 (es) | 2016-03-22 | 2023-08-03 | Hoffmann La Roche | Moléculas biespecíficas para linfocitos T activadas por proteasa |
| PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
| JP7164544B2 (ja) * | 2017-04-11 | 2022-11-01 | インヒブルクス インコーポレイテッド | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 |
| CN111587124B (zh) | 2017-06-23 | 2024-01-12 | 维洛斯生物股份有限公司 | Ror1抗体免疫缀合物 |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019016381A1 (en) * | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES |
| KR102486090B1 (ko) | 2017-08-07 | 2023-01-10 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| CN107827984B (zh) * | 2017-09-13 | 2021-03-16 | 张慧林 | 嵌合抗ROR1抗体Fab分子及其制备方法和应用 |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| EP3749361A1 (en) | 2018-02-08 | 2020-12-16 | F. Hoffmann-La Roche AG | Bispecific antigen-binding molecules and methods of use |
| TWI829667B (zh) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| AU2019243665B2 (en) | 2018-03-30 | 2023-06-01 | Merus N.V. | Multivalent antibody |
| CN112218686A (zh) | 2018-04-11 | 2021-01-12 | 印希比股份有限公司 | 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途 |
| AU2019256431B2 (en) * | 2018-04-18 | 2026-01-15 | Exelixis, Inc. | Anti-ror antibody constructs |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN112867735B (zh) * | 2018-09-07 | 2025-05-09 | 埃泰美德(香港)有限公司 | 双特异性抗原结合蛋白及其用途 |
| JP2022504802A (ja) * | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | ５ｔ４シングルドメイン抗体およびその治療組成物 |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| JP7446342B2 (ja) * | 2019-06-19 | 2024-03-08 | エフ． ホフマン－ラ ロシュ アーゲー | 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法 |
| CR20220019A (es) * | 2019-07-31 | 2022-02-11 | Hoffmann La Roche | Anticuerpos que se fijan a gprc5d |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| EP4168447A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibodies binding to cd3 and cd19 |
| CN113480656B (zh) * | 2020-08-24 | 2022-06-03 | 岸迈生物科技(苏州)有限公司 | 抗ror1抗体 |
| EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| KR20220095163A (ko) * | 2020-12-29 | 2022-07-06 | 삼성바이오로직스 주식회사 | 이중 또는 다중 특이적 항체 |
| PE20250740A1 (es) * | 2021-02-02 | 2025-03-13 | Numab Therapeutics AG | Anticuerpos multiespecificos con especificidad para ror1 y cd3 |
| CN117321078A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药 |
| WO2024178202A2 (en) * | 2023-02-23 | 2024-08-29 | Adanate, Inc. | Anti-cd3 antibodies and methods for their use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591087A (en) * | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| EP2496605A1 (en) * | 2009-11-02 | 2012-09-12 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
| EP3219731A1 (en) * | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| US9758586B2 (en) * | 2010-12-01 | 2017-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| WO2013026837A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| JP6371059B2 (ja) * | 2011-10-31 | 2018-08-08 | 中外製薬株式会社 | 重鎖と軽鎖の会合が制御された抗原結合分子 |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR20150013188A (ko) * | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 |
| JP6444874B2 (ja) * | 2012-10-08 | 2018-12-26 | ロシュ グリクアート アーゲー | ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法 |
| NZ708182A (en) * | 2013-02-26 | 2019-08-30 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| ES2790420T3 (es) * | 2013-03-14 | 2020-10-27 | Scripps Research Inst | Conjugados de anticuerpos y de agentes de focalización usos de los mismos |
| US11634502B2 (en) * | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
-
2015
- 2015-10-08 AU AU2015329966A patent/AU2015329966A1/en not_active Abandoned
- 2015-10-08 CA CA2963696A patent/CA2963696A1/en not_active Abandoned
- 2015-10-08 WO PCT/EP2015/073309 patent/WO2016055593A1/en not_active Ceased
- 2015-10-08 US US15/517,329 patent/US20170306044A1/en not_active Abandoned
- 2015-10-08 EP EP15778295.4A patent/EP3204416A1/en not_active Withdrawn
- 2015-10-08 JP JP2017518516A patent/JP2017536341A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536341A5 (Direct) | ||
| TWI767899B (zh) | Psma及cd3雙特異性t細胞嚙合抗體構築體 | |
| US20230348584A1 (en) | Use of anti-fam19a5 antibodies for treating cancers | |
| JP2022068161A (ja) | 新規抗ｐｄ－ｌ１抗体 | |
| RU2363706C2 (ru) | Антитела к рецептору инсулиноподобного фактора роста i и их применение | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| EP3702373B9 (en) | Anti-pd1 antibodies and their use as therapeutics and diagnostics | |
| JP2018502050A5 (Direct) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2020516240A5 (Direct) | ||
| JPWO2019246514A5 (Direct) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| US20240209078A1 (en) | Multitargeting bispecific antigen-binding molecules of increased selectivity | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| JP2025508118A (ja) | 新規免疫調節剤の開発および使用 | |
| JP7802858B2 (ja) | チェックポイント分子に対する多重特異性結合性構築物およびその使用 | |
| KR20160131061A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| TW202313683A (zh) | 抗nkg2a抗體及組合物 | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| KR20230012559A (ko) | 암 치료를 위한 결합 분자 | |
| AU2023329054A1 (en) | Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor | |
| WO2022268168A1 (zh) | 靶向lag-3和pd-l1的新型双特异抗体及其应用 | |
| HK40106092A (zh) | 抗nkg2a抗体和组合物 | |
| TH1901000369A (th) | แอนติ-gprc5d แอนติบอดี, โมเลกุลที่ยึดเหนี่ยวแอนติเจนแบบมีสองความจำเพาะซึ่งยึดเหนี่ยวgprc5d และ cd3 และการใช้สิ่งดังกล่าว |